Section Edited by Jason J. Luke, MD, FACP and Douglas G. McNeel, MD, PhD
Clinical trials: prospective studies including first-in-man clinical trials, phase II/III clinical studies, and immune monitoring investigations. Small, single institution-based retrospective reports are discouraged.
Preclinical studies: studies that lead to mechanistic understanding or novel development of agents and combination therapies directly relevant to human immunotherapy.
MDR1-expressing CD4 T cells with Th1.17 features resist to neoadjuvant chemotherapy and are associated with breast cancer clinical responseAnthony Di Roio, Margaux Hubert, Laurie Besson, Marion Bossennec, Céline Rodriguez, Yenkel Grinberg-Bleyer, Guilhem Lalle, Lyvia Moudombi, Raphael Schneider, Cyril Degletagne, Isabelle Treilleux, Daniel J Campbell, Séverine Metzger, Thomas Duhen, Olivier TrédanSee the full list of authors
8 November 2023
Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironmentWeiwei Lin, Yikai Luo, Jie Wu, Haowan Zhang, Ge Jin, Chahua Guo, Hang Zhou, Han Liang, Xiaoyan Xu
7 November 2023
Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinomaManon de Vries-Brilland, Nathalie Rioux-Leclercq, Maxime Meylan, Jonathan Dauvé, Christophe Passot, Elena Spirina-Menand, Ronan Flippot, Gaëlle Fromont, Gwenaelle Gravis, Lionnel Geoffrois, Christine Chevreau, Fréderic Rolland, Ellen Blanc, Félix Lefort, Alain RavaudSee the full list of authors
7 November 2023
Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockadeYan Luo, Barath Shreeder, James W Jenkins, Huashan Shi, Purushottam Lamichhane, Kexun Zhou, Deborah A Bahr, Sophia Kurian, Katherine A Jones, Joshua I Daum, Navnita Dutta, Brian M Necela, Martin J Cannon, Matthew S Block, Keith L Knutson
2 November 2023
PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expressionZhiwei Zhang, Deping Sun, Hong Tang, Jie Ren, Shilin Yin, Kai Yang
1 November 2023
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumorsRom Leidner, Kevin Conlon, Douglas G McNeel, Andrea Wang-Gillam, Sumati Gupta, Robert Wesolowski, Monica Chaudhari, Nadia Hassounah, Jong Bong Lee, Lang Ho Lee, Jessica A O’Keeffe, Nancy Lewis, George N Pavlakis, John A Thompson
31 October 2023
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesotheliomaKrisztian Homicsko, Panagiota Zygoura, Maxim Norkin, Stephanie Tissot, Nicholas Shakarishvili, Sanjay Popat, Alessandra Curioni-Fontecedro, Mary O'Brien, Anthony Pope, Riyaz Shah, Patricia Fisher, James Spicer, Amy Roy, David Gilligan, Sylvie RusakiewiczSee the full list of authors
25 October 2023
Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapiesNurudeen A Adegoke, Tuba N Gide, Yizhe Mao, Camelia Quek, Ellis Patrick, Matteo S Carlino, Serigne N Lo, Alexander Maxwell Menzies, Ines Pires da Silva, Ismael A Vergara, Georgina Long, Richard A Scolyer, James S Wilmott
21 October 2023
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-DJunsik Park, Jung Bok Lee, Myong Cheol Lim, Byoung-Gie Kim, Jae-Weon Kim, Sunghoon Kim, Chel Hun Choi, Hee Seung Kim, Sang Yoon Park, Jung-Yun Lee,
21 October 2023
Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinomaMinjiang Chen, Pengfei Ma, Yongchang Zhang, Dong Wang, Zhuang Yu, Yujie Fu, Xiaojing Zhao, Mengzhao Wang, Guanglei Zhuang, Ying Jing
19 October 2023